Iovance Biotherapeutics News

Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)

TipRanksMay 14 17:20

Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating

Iovance Biotherapeutics (IOVA) has an average rating of buy and price targets ranging from $19 to $34, according to analysts polled by Capital IQ. Price: 10.85, Change: -0.12, Percent Change: -1.09

MT NewswiresMay 14 00:42

HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics with a Buy and maintains $32 price target.

Analyst UpgradesMay 11 03:21

Iovance Biotherapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 191.31% HC Wainwright & Co. → $32 Reiterates Buy → Buy 03/14/2024 72.96% Piper Sandler $18 → $1

BenzingaMay 11 03:20

Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says

Iovance Biotherapeutics' (IOVA) "disciplined" patient selection for treatment with Amtagvi, an intravenous infusion suspension for treating adults with unresectable or metastatic melanoma, is helping

MT NewswiresMay 11 01:35

Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns With EPS Projections Amidst Strong ...

Yahoo FinanceMay 11 00:55

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents

BenzingaMay 11 00:44

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 11 00:33

Iovance Biotherapeutics's Options: A Look at What the Big Money Is Thinking

Whales with a lot of money to spend have taken a noticeably bearish stance on Iovance Biotherapeutics.Looking at options history for Iovance Biotherapeutics (NASDAQ:IOVA) we detected 17 trades.If we c

BenzingaMay 11 00:32

Iovance Biotherapeutics Shares Are Trading Lower Following Q1 Financial Results. The Stock Initially Spiked Higher on the News Yesterday but Has Since Reversed.

Iovance Biotherapeutics Shares Are Trading Lower Following Q1 Financial Results. The Stock Initially Spiked Higher on the News Yesterday but Has Since Reversed.

BenzingaMay 10 22:17

Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

TipRanksMay 10 17:46

Iovance Biotherapeutics: A Strong Buy on Robust Growth Potential and Early Launch Success

TipRanksMay 10 12:56

Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Earnings Call Transcript

Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 10 08:40

Iovance Biotherapeutics | 10-Q: Quarterly report

Futu NewsMay 10 05:16 · Announcements

Iovance Biotherapeutics Q1 Loss Narrows -- Shares Higher After Hours

Iovance Biotherapeutics (IOVA) reported a Q1 net loss late Thursday of $0.42 per diluted share, narrower than a loss of $0.50 a year earlier. Analysts polled by Capital IQ expected a loss of $0.43. Re

MT NewswiresMay 10 04:23

Iovance Biotherapeutics Q1 2024 GAAP EPS $(0.42), Inline, Sales $715.000K Miss $2.075M Estimate

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.42) per share which met the analyst consensus estimate. This is a 16 percent increase over losses of $(0.50) per share from the s

BenzingaMay 10 04:18

Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q1 Revenue $715,000

04:05 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q1 Revenue $715,000

MT NewswiresMay 10 04:05

Iovance Biotherapeutics 1Q Loss/Shr 42c >IOVA

Iovance Biotherapeutics 1Q Loss/Shr 42c >IOVA

Dow JonesMay 10 04:01

Press Release: Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi(TM) (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) A

Dow JonesMay 10 04:01

How Is The Market Feeling About Iovance Biotherapeutics?

Iovance Biotherapeutics's (NYSE:IOVA) short percent of float has risen 8.92% since its last report. The company recently reported that it has 48.98 million shares sold short, which is 19.53% of all re

BenzingaMay 10 01:30